-
2024-512683-53-00
6
2018-05-18
Non-muscle invasive bladder cancer
-
2025-522301-37-00
4
2026-06-24
Nonsegmental vitiligo
-
2025-524078-40-00
5
2026-06-10
Chronic Spontaneous Urticaria
-
2025-521587-35-00
5
2026-06-03
Metastatic colorectal cancer
-
2025-523269-31-00
3
2026-06-02
Hormone receptor-positive early breast cancer in post-menopausal women
-
2025-523461-17-01
5
2026-06-01
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
-
2025-521476-65-00
6
2026-05-28
Severe Gram-Negative Bacterial infections
-
2025-522007-18-00
5
2026-05-27
Relapsed or Refractory Multiple Myeloma
-
2025-520471-29-00
5
2026-05-26
Locally advanced adenocarcinoma of the colon and upper rectum with mic
-
2025-522848-40-00
6
2026-05-07
Early Breast Cancer
-
2025-521865-29-00
4
2026-04-30
moderate-to-severe hidradenitis suppurativa
-
2025-524366-21-00
5
2026-04-29
treatment-naive Chronic Lymphocytic Leukemia
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-522440-41-00
4
2026-04-27
Hidradenitis Suppurativa
-
2025-522705-37-00
4
2026-04-21
HIDRADENITIS SUPPURATIVA
-
2023-509220-17-00
7
2026-04-10
Metastatic solid tumors
-
2025-522403-17-00
5
2026-04-10
Nummular Dermatitis
-
2025-523013-28-00
4
2026-04-07
Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
-
2025-521859-23-00
9
2026-03-31
PSMA-positive mCRPC with prior exposure to at least one prior ARPI
-
2025-523347-35-00
11
2026-03-05
Atopic Dermatitis
-
2025-522421-36-00
6
2026-02-27
Acute coronary syndrome
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2025-521904-23-00
4
2026-02-17
Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to